- Home
- STI vs PHGE Comparison
STI vs PHGE Comparison
Compare STI & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STI
- PHGE
- Stock Information
- Founded
- STI 2014
- PHGE 2015
- Country
- STI United States
- PHGE Israel
- Employees
- STI N/A
- PHGE N/A
- Industry
- STI
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- STI
- PHGE Health Care
- Exchange
- STI NYSE
- PHGE Nasdaq
- Market Cap
- STI 9.5M
- PHGE 11.0M
- IPO Year
- STI N/A
- PHGE N/A
- Fundamental
- Price
- STI $3.64
- PHGE $0.49
- Analyst Decision
- STI
- PHGE Strong Buy
- Analyst Count
- STI 0
- PHGE 1
- Target Price
- STI N/A
- PHGE $15.00
- AVG Volume (30 Days)
- STI 74.6K
- PHGE 278.8K
- Earning Date
- STI 08-12-2025
- PHGE 08-13-2025
- Dividend Yield
- STI N/A
- PHGE N/A
- EPS Growth
- STI N/A
- PHGE N/A
- EPS
- STI 6.72
- PHGE N/A
- Revenue
- STI N/A
- PHGE N/A
- Revenue This Year
- STI N/A
- PHGE N/A
- Revenue Next Year
- STI N/A
- PHGE N/A
- P/E Ratio
- STI $0.56
- PHGE N/A
- Revenue Growth
- STI N/A
- PHGE N/A
- 52 Week Low
- STI $2.94
- PHGE $0.34
- 52 Week High
- STI $55.00
- PHGE $3.86
- Technical
- Relative Strength Index (RSI)
- STI 49.92
- PHGE 51.35
- Support Level
- STI $3.22
- PHGE $0.34
- Resistance Level
- STI $3.93
- PHGE $0.51
- Average True Range (ATR)
- STI 0.27
- PHGE 0.05
- MACD
- STI 0.12
- PHGE 0.01
- Stochastic Oscillator
- STI 57.61
- PHGE 77.53
About STI SOLIDION TECHNOLOGY INC
Solidion Technology Inc is engaged in researching, developing and manufacturing battery materials and components, as well as the development and production of next-generation batteries for energy storage systems and electric vehicles for ground, air, and sea transportation. It is recognized as a IP leader in both the high-capacity anode and the high-energy solid-state battery.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).